Anders Mellemgaard

11.6k total citations · 3 hit papers
144 papers, 7.6k citations indexed

About

Anders Mellemgaard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anders Mellemgaard has authored 144 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 87 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Anders Mellemgaard's work include Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (31 papers) and Lung Cancer Diagnosis and Treatment (27 papers). Anders Mellemgaard is often cited by papers focused on Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (31 papers) and Lung Cancer Diagnosis and Treatment (27 papers). Anders Mellemgaard collaborates with scholars based in Denmark, United States and United Kingdom. Anders Mellemgaard's co-authors include Jørgen H. Olsen, Joachim von Pawel, Henrik Møller, Giorgio V. Scagliotti, Mauro Zukin, Christian Manegold, Lorinda Simms, Purvish Parikh, Filippo de Marinis and David R. Gandara and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Anders Mellemgaard

143 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

2008 2.5k citations Giorgio V. Scagliotti, Purvish Parikh et al. Journal of Clinical Oncology profile →
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

2014 694 citations Martin Reck, R. Kaiser et al. profile →
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Sergey Orlov, Remy B. Verheijen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anders Mellemgaard Denmark	41	4.6k	4.1k	1.9k	1.1k	994	144	7.6k
Gregory P. Kalemkerian United States	45	3.9k 0.9×	3.9k 0.9×	2.3k 1.2×	1.2k 1.1×	1.4k 1.4×	179	7.8k
Philip Bonomi United States	42	4.4k 1.0×	4.9k 1.2×	2.1k 1.1×	978 0.9×	652 0.7×	241	8.0k
Hideo Kunitoh Japan	43	3.5k 0.8×	3.5k 0.8×	2.0k 1.0×	1.1k 1.0×	655 0.7×	217	6.5k
Kaoru Kubota Japan	44	3.7k 0.8×	4.4k 1.1×	1.5k 0.8×	740 0.7×	767 0.8×	269	7.1k
Ken Nakagawa Japan	44	5.5k 1.2×	4.0k 1.0×	2.7k 1.4×	1.8k 1.6×	1.0k 1.0×	319	9.6k
Peter Venner Canada	40	4.8k 1.1×	3.3k 0.8×	1.9k 1.0×	1.5k 1.4×	462 0.5×	116	8.4k
Vittorio Gebbia Italy	40	2.2k 0.5×	4.2k 1.0×	1.0k 0.5×	1.0k 0.9×	627 0.6×	290	7.0k
Daniel D. Karp United States	43	3.8k 0.8×	4.8k 1.2×	2.9k 1.5×	1.6k 1.4×	450 0.5×	217	9.4k
Ikuo Sekine Japan	38	3.0k 0.7×	3.3k 0.8×	1.3k 0.7×	742 0.7×	743 0.7×	228	5.8k
Jee Hyun Kim South Korea	43	2.9k 0.6×	5.2k 1.3×	1.5k 0.8×	1.4k 1.2×	429 0.4×	320	8.1k

Countries citing papers authored by Anders Mellemgaard

Since Specialization

Citations

This map shows the geographic impact of Anders Mellemgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Mellemgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Mellemgaard more than expected).

Fields of papers citing papers by Anders Mellemgaard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Mellemgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Mellemgaard. The network helps show where Anders Mellemgaard may publish in the future.

Co-authorship network of co-authors of Anders Mellemgaard

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Mellemgaard. A scholar is included among the top collaborators of Anders Mellemgaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Mellemgaard. Anders Mellemgaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Albigès, Laurence, Daniel Y.C. Heng, Jae‐Lyun Lee, et al.. (2022). Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. European Journal of Cancer. 170. 158–168. 7 indexed citations

Dalton, Susanne Oksbjerg, et al.. (2022). Association between Health-Related Quality of Life and Completion of First-Line Treatment among Lung Cancer Patients. Cancers. 14(14). 3343–3343. 4 indexed citations

Yoh, Kiyotaka, Tomonori Hirashima, Hideo Saka, et al.. (2021). Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Targeted Oncology. 16(3). 339–355. 9 indexed citations

Helland, Åslaug, Simon Ekman, Anders Mellemgaard, et al.. (2020). Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Lung Cancer. 143. 27–35. 43 indexed citations

Hirashima, T., Kiyotaka Yoh, Hideo Saka, et al.. (2020). 387P Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C. Annals of Oncology. 31. S1393–S1393. 1 indexed citations

Yang, Jin‐Ji, Jian Fang, Yongqian Shu, et al.. (2020). A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Investigational New Drugs. 39(2). 477–487. 43 indexed citations

Reck, Martin, Anders Mellemgaard, Silvia Novello, et al.. (2018). Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study. OncoTargets and Therapy. Volume 11. 4573–4582. 13 indexed citations

Kjær, Trille Kristina, Anders Mellemgaard, Bo Andreassen Rix, et al.. (2017). Recruiting newly referred lung cancer patients to a patient navigator intervention (PACO): lessons learnt from a pilot study. Acta Oncologica. 56(2). 335–341. 9 indexed citations

Kjeldsen, Julie Westerlin, et al.. (2017). Long-term follow-up results of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with an epitope derived from Indoleamine 2,3 Dioxygenase (IDO) in a phase I study. Annals of Oncology. 28. v473–v473. 1 indexed citations

10.

Gaschler‐Markefski, Birgit, John V. Heymach, Maya Gottfried, et al.. (2017). Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. ESMO Open. 2(1). e000102–e000102. 9 indexed citations

11.

Heigener, David F., Maya Gottfried, Jaafar Bennouna, et al.. (2016). Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study. Annals of Oncology. 27. vi442–vi442. 2 indexed citations

12.

Sibolt, Patrik, et al.. (2015). Monte Carlo calculations support organ sparing in Deep-Inspiration Breath-Hold intensity-modulated radiotherapy for locally advanced lung cancer. Radiotherapy and Oncology. 117(1). 55–63. 9 indexed citations

13.

Dalton, Susanne Oksbjerg, Marianne Steding‐Jessen, Erik Jakobsen, et al.. (2015). Socioeconomic position and survival after lung cancer: Influence of stage, treatment and comorbidity among Danish patients with lung cancer diagnosed in 2004–2010. Acta Oncologica. 54(5). 797–804. 51 indexed citations

14.

Iversen, Trine Zeeberg, Lotte Engell-Noerregaard, Eva Ellebæk, et al.. (2013). Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase. Clinical Cancer Research. 20(1). 221–232. 100 indexed citations

15.

Krasnik, Mark, Anders Mellemgaard, & Erik Jakobsen. (2011). Does routine use of EBUS-TBNA and EUS-FNA improve the accuracy of staging of non small cell lung cancer patients – A national tumor registry based study. European Respiratory Journal. 38(Suppl 55). p1969–p1969. 1 indexed citations

16.

Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(21). 3543–3551. 2487 indexed citations breakdown →

17.

Wolk, Alicja, Shelley Niwa, Per Lindblad, et al.. (1996). International renal cell cancer study. VII. role of diet. International Journal of Cancer. 65(1). 67–73. 137 indexed citations

18.

Wolk, Alicja, Gloria Gridley, Shelley Niwa, et al.. (1996). International renal cell cancer study. VII. role of diet. International Journal of Cancer. 65(1). 67–73. 13 indexed citations

19.

Mellemgaard, Anders, Henrik Møller, Jørgen H. Olsen, & Ole Møller Jensen. (1991). Increased Risk of Renal Cell Carcinoma Among Obese Women. JNCI Journal of the National Cancer Institute. 83(21). 1581–1582. 26 indexed citations

20.

Mellemgaard, Anders, Ole Møller Jensen, & Elsebeth Lynge. (1989). Cancer incidence among spouses of patients with colorectal cancer. International Journal of Cancer. 44(2). 225–228. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact